Skip Navigation

European Heart Journal 2001 22(9):717-719; doi:10.1053/euhj.2000.2332
Copyright © 2001 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Chambers, J.C.
Right arrow Articles by Kooner, J.S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chambers, J.C.
Right arrow Articles by Kooner, J.S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Hotline Editorials

Homocysteine — an innocent bystander in vascular disease?

J.C. Chambers and J.S. Kooner

National Heart and Lung Institute, Imperial College School of Medicine, London, U.K.

References

  1. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med. 1998;338:1042–1050[Free Full Text]
  2. McCully KS. Vascular pathology of homocyst(e)inemia: implications for the development of arteriosclerosis. Am J Pathol. 1969;56:111–128[ISI][Medline]
  3. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA. 1995;274:1049–1057[Abstract]
  4. Danesh J, Lewington S. Plasma homocysteine and coronary heart disease: systematic review of published epidemiological studies. J Cardiovasc Risk. 1998;5:229–232[Medline]
  5. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 1997;337:230–236[Abstract/Free Full Text]
  6. Alfthan G, Aro A, Gey KF. Plasma homocysteine and cardiovascular disease mortality. Lancet. 1997;349:97
  7. Chambers JC, Obeid OA, Refsum H. Plasma homocysteine concentrations and risk of coronary heart disease in UK Indian Asian and European men. Lancet. 2000;355:523–527[CrossRef][ISI][Medline]
  8. Chambers JC, Ireland H, Thompson E. The methylenetetrahydrofolate reductase 677 C->T mutation, and coronary heart disease risk in UK Indian Asians. Arterioscler Thromb Vasc Biol. 2000;:
  9. Dudman NP. An alternative view of homocysteine. Lancet. 1999;354:2072–2074[CrossRef][ISI][Medline]
  10. Chambers JC, McGregor A, Jean Marie J, Kooner JS. Acute hyperhomocysteinaemia and endothelial dysfunction. Lancet. 1997;351:36–37
  11. Chambers JC, McGregor A, Jean Marie J, Obeid OA, Kooner JS. Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia: an effect reversible with vitamin C therapy. Circulation. 1999;99:1156–1160[Abstract/Free Full Text]
  12. Chambers JC, Obeid OA, Kooner JS. Physiological increments in plasma homocysteine induce vascular endothelial dysfunction in normal human subjects. Arterioscler Thromb Vasc Biol. 1999;19:2922–2927[Abstract/Free Full Text]
  13. Bellamy MF, McDowell IF, Ramsey MW. Hyperhomocysteinemia after an oral methionine load acutely impairs endothelial function in healthy adults. Circulation. 1998;98:1848–1852[Abstract/Free Full Text]
  14. Kanani PM, Sinkey CA, Browning RL, Allaman M, Knapp HR, Haynes WG. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocysteinaemia in humans. Circulation. 1999;100:1161–1168[Abstract/Free Full Text]
  15. Stamler JS, Osborne JA, Jaraki O. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest. 1993;91:308–318[ISI][Medline]
  16. Blundell G, Jones BG, Rose FA, Tudball N. Homocysteine mediated endothelial cell toxicity and its amelioration. Atherosclerosis. 1996;122:163–172[CrossRef][ISI][Medline]
  17. Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest. 1996;98:5–7[ISI][Medline]
  18. Ventura P, Panini R, Verlato C, Scarpetta G, Salvioli G. Peroxidation indices and total antioxidant capacity in plasma during hyperhomocysteinemia induced by methionine oral loading. Metabolism. 2000;49:225–228[CrossRef][ISI][Medline]
  19. Voutilainen S, Morrow JD, Roberts LJ. Enhanced in vivo lipid peroxidation at elevated plasma total homocysteine levels. Arterioscler Thromb Vasc Biol. 1999;19:1263–1266[Abstract/Free Full Text]
  20. Clarke R, Collins R. Can dietary supplements with folic acid or vitamin B6 reduce cardiovascular risk? Design of clinical trials to test the homocysteine hypothesis of vascular disease. J Cardiovasc Risk. 1998;5:249–255[Medline]
  21. Bellamy MF, McDowell IF, Ramsey MW, Brownlee M, Newcombe RG, Lewis MJ. Oral folate enhances endothelial function in hyperhomocysteinaemic subjects. Eur J Clin Invest. 1999;29:659–662[CrossRef][ISI][Medline]
  22. Woo KS, Chook P, Lolin YI, Sanderson JE, Metreweli C, Celermajer DS. Folic acid improves arterial endothelial function in adults with hyperhomocystinemia. J Am Coll Cardiol. 1999;34:2002–2006[Abstract/Free Full Text]
  23. Chambers JC, Ueland PM, Obeid OA, Wrigley J, Refsum H, Kooner JS. Improved vascular endothelial function after oral B vitamins; an effect mediated through reduced concentrations of free plasma homocysteine. Circulation. 2000;:
  24. van den BM, Boers GH, Franken DG. Hyperhomocysteinaemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease. Eur J Clin Invest. 1995;25:176–181[ISI][Medline]
  25. Vermeulen EG, Stehouwer CD, Twisk JW. Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial. Lancet. 2000;355:517–522[CrossRef][ISI][Medline]
  26. Bostom AG, Garber C. Endpoints for homocysteine-lowering trials. Lancet. 2000;355:511–512[CrossRef][ISI][Medline]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 HeartHome page
C-K Wong, C J K Hammett, R The, J K French, W Gao, B J Webber, J M Elliott, A W Hamer, J A Ormiston, M W I Webster, et al.
Lack of association between baseline plasma homocysteine concentrations and restenosis rates after a first elective percutaneous coronary intervention without stenting
Heart, November 1, 2004; 90(11): 1299 - 1302.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Chambers, J.C.
Right arrow Articles by Kooner, J.S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chambers, J.C.
Right arrow Articles by Kooner, J.S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?